Cargando...
Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report
Lenalidomide has been developed as the derivative of thalidomide that has fewer side effects. We herein report a rare case of castration‐resistant prostate cancer successfully maintained using lenalidomide for multiple myeloma.
Guardado en:
| Publicado en: | Clin Case Rep |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5799614/ https://ncbi.nlm.nih.gov/pubmed/29445483 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.1328 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|